Published in Osteoporos Int on March 02, 2011
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int (2015) 0.93
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (2016) 0.92
Frax prediction without BMD for assessment of osteoporotic fracture risk. Endocr Pract (2013) 0.85
FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int (2013) 0.81
A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int (2012) 0.81
Prediction of fracture risk in men: a cohort study. J Bone Miner Res (2012) 0.81
The discriminative ability of FRAX, the WHO algorithm, to identify women with prevalent asymptomatic vertebral fractures: a cross-sectional study. BMC Musculoskelet Disord (2014) 0.79
Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women? Osteoporos Int (2013) 0.78
Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry. Osteoporos Int (2015) 0.77
Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clin Rheumatol (2014) 0.77
How to predict the risk of fracture in HIV? Curr Opin HIV AIDS (2016) 0.75
How can gynaecologists cope with the silent killer - osteoporosis? Prz Menopauzalny (2017) 0.75
FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporos Int (2017) 0.75
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
FRAX and its applications to clinical practice. Bone (2009) 3.32
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab (2008) 1.66
Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res (2003) 1.56
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (2009) 1.41
Filtering FRAX. Osteoporos Int (2010) 1.40
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab (2006) 1.39
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Construction and validation of a population-based bone densitometry database. J Clin Densitom (2005) 1.24
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone (2010) 1.12
Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care (1999) 1.07
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res (2004) 0.98
A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int (2004) 0.90
The importance of spectrum bias on bone density monitoring in clinical practice. Bone (2006) 0.86
The US FRAX filter: avoiding confusion or hindering progress? Osteoporos Int (2010) 0.77
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1995) 3.79
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
The components of excess mortality after hip fracture. Bone (2003) 2.63
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg (2002) 2.41
Bone-density measurement. Lancet (1992) 2.38
Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res (2012) 2.22
Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg (1997) 2.21
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.09
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat (2009) 1.90
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Long-term follow-up of patients with untreated scoliosis. A study of mortality, causes of death, and symptoms. Spine (Phila Pa 1976) (1992) 1.88
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74
Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer (1990) 1.73
Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke (2001) 1.73
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J (2007) 1.71
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg (2005) 1.68
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res (2011) 1.68
Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy. Diabet Med (2006) 1.63
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab (2012) 1.61
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer (1995) 1.60
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Position sense acuity is diminished following repetitive low-intensity work to fatigue in a simulated occupational setting. Eur J Appl Physiol (2000) 1.57
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Estimation of the parenchymal-cell content of the parathyroid gland, using density-gradient columns. Preliminary report. Acta Pathol Microbiol Scand A (1977) 1.52
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47